Taken together with these recent findings, our results suggest that LXR agonists not only increased apoE synthesis and lipidation, but also led to reduced levels of apoE receptors in the brain, which could result in further improvement of apoE-bound amyloid clearance from the CNS. The gene discussed is APOE; the disease is amyloidosis.